Venlafaxine HCl

Product overview

Venlafaxine HCl pellets deliver extended-release SNRI therapy for depression and anxiety management. Rraynex layers venlafaxine onto inert cores under controlled humidity, followed by polymer coatings tuned to release the active gradually over 24 hours. Pellets maintain a narrow particle size distribution and low friability, ensuring blend uniformity in capsules and multiparticulate tablets. Quality checks cover potency, residual solvents, and dissolution to guarantee the extended-release curve remains stable across batches. Our documentation package includes dissolution comparisons against reference products, impurity profiles, and stability studies spanning ICH climatic zones. Packaging offerings - from moisture-resistant drums to small nitrogen-flushed bags - support both commercial supply and clinical development. Technical teams assist with method transfer, capsule lubricant optimization, and compatibility studies involving cellulose or methacrylate polymers. Responsive change-control practices keep regulatory dossiers current, giving partners confidence in venlafaxine supply continuity.